The Pontus Pharma team will manage the promotion of four of JGL’s high-quality dermatological prescription drugs. For the newest drug, a combination of clindamycin and benzoyl peroxide, an agreement was signed for exclusive distribution and promotion. Cooperation was agreed for the markets of Croatia, Slovenia, Serbia, and Bosnia and Herzegovina and represents a further step in strengthening cooperation with dermatologists, pharmacists and healthcare institutions across the region so that high-quality products, which are the basis for treatment, may be as widely available as possible to all those who need them.
Within the framework of the newly agreed upon partnership, the audience and lecturers from the expert symposium “Local Treatment and Skincare Options” in Opatija visited JGL’s production facilities. Alenka Jajac Knez, Market Operations Director at JGL, greeted the visitors before their tour, while Vladimir Maleš, Production Department Manager, was their expert guide through the production and storage facilities of the JGL Pharma Valley complex. The visit was organised by Darko Pejnović, Country Manager for Croatia and Southeast Europe, and Igor Haralović, Founder and Managing Director at Pontus Pharma.
“JGL is a leader in the acne therapeutics segment in the markets of Ukraine, Kazakhstan, Belarus and Russia. Of special note is that our new product in our portfolio, clindamycin 10 mg/g + benzoyl peroxide 50 mg/g gel, the result of our in-house development, will soon be launched on the Croatian market under the brand Aknet Duo through our cooperation with Pontus Pharma”, said Alenka Jajac Knez and added that this product is already present in highly regulated western markets, such as in UK, Austria, Germany, Italy and Spain.